mhh es1 cells  (CLS Cell Lines Service GmbH)


Bioz Verified Symbol CLS Cell Lines Service GmbH is a verified supplier
Bioz Manufacturer Symbol CLS Cell Lines Service GmbH manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    CLS Cell Lines Service GmbH mhh es1 cells
    Relationship between BRCA status and PARP inhibitor efficacy in breast and Ewing’s sarcoma cell lines.
    Mhh Es1 Cells, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mhh es1 cells/product/CLS Cell Lines Service GmbH
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mhh es1 cells - by Bioz Stars, 2024-05
    90/100 stars

    Images

    1) Product Images from "Single cell resolution in vivo imaging of DNA damage following PARP inhibition"

    Article Title: Single cell resolution in vivo imaging of DNA damage following PARP inhibition

    Journal: Scientific Reports

    doi: 10.1038/srep10129

    Relationship between BRCA status and PARP inhibitor efficacy in breast and Ewing’s sarcoma cell lines.
    Figure Legend Snippet: Relationship between BRCA status and PARP inhibitor efficacy in breast and Ewing’s sarcoma cell lines.

    Techniques Used: In Vitro, In Vivo

    ( a ) Representative images of single cells from an MHH-ES1 tumor prior to treatment and after eight days of 100 mg/kg Olaparib. Images are separated into ≤2 foci per nucleus (2 is the average number of foci per nucleus pre-treatment) and >2 foci per nucleus. Percentage values at the bottom represent the percentage of the total number of nuclei that fall into either of these groups. ( b and c ) Single cell data for a nu/nu mouse with a Ewing’s sarcoma tumor xenograft (MHH-ES1 cells) that was treated for the duration of imaging with vehicle alone ( b , 10% DMAC/Solutol in PBS) or with 100 mg/kg Olaparib ( c ). Note for b and c, each point represents the number of foci in a single nucleus, with 200–600 single cells analyzed for each day of imaging. The black line represents the mean number of foci per nucleus for each day of imaging.
    Figure Legend Snippet: ( a ) Representative images of single cells from an MHH-ES1 tumor prior to treatment and after eight days of 100 mg/kg Olaparib. Images are separated into ≤2 foci per nucleus (2 is the average number of foci per nucleus pre-treatment) and >2 foci per nucleus. Percentage values at the bottom represent the percentage of the total number of nuclei that fall into either of these groups. ( b and c ) Single cell data for a nu/nu mouse with a Ewing’s sarcoma tumor xenograft (MHH-ES1 cells) that was treated for the duration of imaging with vehicle alone ( b , 10% DMAC/Solutol in PBS) or with 100 mg/kg Olaparib ( c ). Note for b and c, each point represents the number of foci in a single nucleus, with 200–600 single cells analyzed for each day of imaging. The black line represents the mean number of foci per nucleus for each day of imaging.

    Techniques Used: Imaging

    ( a ) Representative single-cell data showing the number of foci on a per nucleus basis for a mouse treated daily with 50 mg/kg olaparib (IP). Each point indicates the number of foci in a single nucleus, with black lines on each day representing the mean number of foci. ( b ) Comparison of the fold change in the number of foci for the 50 mg/kg (red, n = 2) and 100 mg/kg (blue, n = 3, same data as in for comparison) olaparib doses (relative to day 0 prior to olaparib treatment). Error bars represent the standard error of the mean. ( c ) Comparison of cell viability following treatment with increasing concentrations of olaparib for 6 days in MHH-ES1 cells grown in culture alone (red) or grown in vivo and then dissociated and re-grown in cell culture at the endpoint of olaparib treatment/imaging (blue). Data were fit to a sigmoidal dose-response curve using Prism (GraphPad), with error bars representing the standard error of the mean.
    Figure Legend Snippet: ( a ) Representative single-cell data showing the number of foci on a per nucleus basis for a mouse treated daily with 50 mg/kg olaparib (IP). Each point indicates the number of foci in a single nucleus, with black lines on each day representing the mean number of foci. ( b ) Comparison of the fold change in the number of foci for the 50 mg/kg (red, n = 2) and 100 mg/kg (blue, n = 3, same data as in for comparison) olaparib doses (relative to day 0 prior to olaparib treatment). Error bars represent the standard error of the mean. ( c ) Comparison of cell viability following treatment with increasing concentrations of olaparib for 6 days in MHH-ES1 cells grown in culture alone (red) or grown in vivo and then dissociated and re-grown in cell culture at the endpoint of olaparib treatment/imaging (blue). Data were fit to a sigmoidal dose-response curve using Prism (GraphPad), with error bars representing the standard error of the mean.

    Techniques Used: In Vivo, Cell Culture, Imaging

    mhh es1 cells  (CLS Cell Lines Service GmbH)


    Bioz Verified Symbol CLS Cell Lines Service GmbH is a verified supplier
    Bioz Manufacturer Symbol CLS Cell Lines Service GmbH manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90

    Structured Review

    CLS Cell Lines Service GmbH mhh es1 cells
    Relationship between BRCA status and PARP inhibitor efficacy in breast and Ewing’s sarcoma cell lines.
    Mhh Es1 Cells, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mhh es1 cells/product/CLS Cell Lines Service GmbH
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mhh es1 cells - by Bioz Stars, 2024-05
    90/100 stars

    Images

    1) Product Images from "Single cell resolution in vivo imaging of DNA damage following PARP inhibition"

    Article Title: Single cell resolution in vivo imaging of DNA damage following PARP inhibition

    Journal: Scientific Reports

    doi: 10.1038/srep10129

    Relationship between BRCA status and PARP inhibitor efficacy in breast and Ewing’s sarcoma cell lines.
    Figure Legend Snippet: Relationship between BRCA status and PARP inhibitor efficacy in breast and Ewing’s sarcoma cell lines.

    Techniques Used: In Vitro, In Vivo

    ( a ) Representative images of single cells from an MHH-ES1 tumor prior to treatment and after eight days of 100 mg/kg Olaparib. Images are separated into ≤2 foci per nucleus (2 is the average number of foci per nucleus pre-treatment) and >2 foci per nucleus. Percentage values at the bottom represent the percentage of the total number of nuclei that fall into either of these groups. ( b and c ) Single cell data for a nu/nu mouse with a Ewing’s sarcoma tumor xenograft (MHH-ES1 cells) that was treated for the duration of imaging with vehicle alone ( b , 10% DMAC/Solutol in PBS) or with 100 mg/kg Olaparib ( c ). Note for b and c, each point represents the number of foci in a single nucleus, with 200–600 single cells analyzed for each day of imaging. The black line represents the mean number of foci per nucleus for each day of imaging.
    Figure Legend Snippet: ( a ) Representative images of single cells from an MHH-ES1 tumor prior to treatment and after eight days of 100 mg/kg Olaparib. Images are separated into ≤2 foci per nucleus (2 is the average number of foci per nucleus pre-treatment) and >2 foci per nucleus. Percentage values at the bottom represent the percentage of the total number of nuclei that fall into either of these groups. ( b and c ) Single cell data for a nu/nu mouse with a Ewing’s sarcoma tumor xenograft (MHH-ES1 cells) that was treated for the duration of imaging with vehicle alone ( b , 10% DMAC/Solutol in PBS) or with 100 mg/kg Olaparib ( c ). Note for b and c, each point represents the number of foci in a single nucleus, with 200–600 single cells analyzed for each day of imaging. The black line represents the mean number of foci per nucleus for each day of imaging.

    Techniques Used: Imaging

    ( a ) Representative single-cell data showing the number of foci on a per nucleus basis for a mouse treated daily with 50 mg/kg olaparib (IP). Each point indicates the number of foci in a single nucleus, with black lines on each day representing the mean number of foci. ( b ) Comparison of the fold change in the number of foci for the 50 mg/kg (red, n = 2) and 100 mg/kg (blue, n = 3, same data as in for comparison) olaparib doses (relative to day 0 prior to olaparib treatment). Error bars represent the standard error of the mean. ( c ) Comparison of cell viability following treatment with increasing concentrations of olaparib for 6 days in MHH-ES1 cells grown in culture alone (red) or grown in vivo and then dissociated and re-grown in cell culture at the endpoint of olaparib treatment/imaging (blue). Data were fit to a sigmoidal dose-response curve using Prism (GraphPad), with error bars representing the standard error of the mean.
    Figure Legend Snippet: ( a ) Representative single-cell data showing the number of foci on a per nucleus basis for a mouse treated daily with 50 mg/kg olaparib (IP). Each point indicates the number of foci in a single nucleus, with black lines on each day representing the mean number of foci. ( b ) Comparison of the fold change in the number of foci for the 50 mg/kg (red, n = 2) and 100 mg/kg (blue, n = 3, same data as in for comparison) olaparib doses (relative to day 0 prior to olaparib treatment). Error bars represent the standard error of the mean. ( c ) Comparison of cell viability following treatment with increasing concentrations of olaparib for 6 days in MHH-ES1 cells grown in culture alone (red) or grown in vivo and then dissociated and re-grown in cell culture at the endpoint of olaparib treatment/imaging (blue). Data were fit to a sigmoidal dose-response curve using Prism (GraphPad), with error bars representing the standard error of the mean.

    Techniques Used: In Vivo, Cell Culture, Imaging

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 90
    CLS Cell Lines Service GmbH mhh es1 cells
    Relationship between BRCA status and PARP inhibitor efficacy in breast and Ewing’s sarcoma cell lines.
    Mhh Es1 Cells, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mhh es1 cells/product/CLS Cell Lines Service GmbH
    Average 90 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    mhh es1 cells - by Bioz Stars, 2024-05
    90/100 stars
      Buy from Supplier

    Image Search Results


    Relationship between BRCA status and PARP inhibitor efficacy in breast and Ewing’s sarcoma cell lines.

    Journal: Scientific Reports

    Article Title: Single cell resolution in vivo imaging of DNA damage following PARP inhibition

    doi: 10.1038/srep10129

    Figure Lengend Snippet: Relationship between BRCA status and PARP inhibitor efficacy in breast and Ewing’s sarcoma cell lines.

    Article Snippet: MHH-ES1 cells were purchased from CLS Cell Lines Service (order # 300136).

    Techniques: In Vitro, In Vivo

    ( a ) Representative images of single cells from an MHH-ES1 tumor prior to treatment and after eight days of 100 mg/kg Olaparib. Images are separated into ≤2 foci per nucleus (2 is the average number of foci per nucleus pre-treatment) and >2 foci per nucleus. Percentage values at the bottom represent the percentage of the total number of nuclei that fall into either of these groups. ( b and c ) Single cell data for a nu/nu mouse with a Ewing’s sarcoma tumor xenograft (MHH-ES1 cells) that was treated for the duration of imaging with vehicle alone ( b , 10% DMAC/Solutol in PBS) or with 100 mg/kg Olaparib ( c ). Note for b and c, each point represents the number of foci in a single nucleus, with 200–600 single cells analyzed for each day of imaging. The black line represents the mean number of foci per nucleus for each day of imaging.

    Journal: Scientific Reports

    Article Title: Single cell resolution in vivo imaging of DNA damage following PARP inhibition

    doi: 10.1038/srep10129

    Figure Lengend Snippet: ( a ) Representative images of single cells from an MHH-ES1 tumor prior to treatment and after eight days of 100 mg/kg Olaparib. Images are separated into ≤2 foci per nucleus (2 is the average number of foci per nucleus pre-treatment) and >2 foci per nucleus. Percentage values at the bottom represent the percentage of the total number of nuclei that fall into either of these groups. ( b and c ) Single cell data for a nu/nu mouse with a Ewing’s sarcoma tumor xenograft (MHH-ES1 cells) that was treated for the duration of imaging with vehicle alone ( b , 10% DMAC/Solutol in PBS) or with 100 mg/kg Olaparib ( c ). Note for b and c, each point represents the number of foci in a single nucleus, with 200–600 single cells analyzed for each day of imaging. The black line represents the mean number of foci per nucleus for each day of imaging.

    Article Snippet: MHH-ES1 cells were purchased from CLS Cell Lines Service (order # 300136).

    Techniques: Imaging

    ( a ) Representative single-cell data showing the number of foci on a per nucleus basis for a mouse treated daily with 50 mg/kg olaparib (IP). Each point indicates the number of foci in a single nucleus, with black lines on each day representing the mean number of foci. ( b ) Comparison of the fold change in the number of foci for the 50 mg/kg (red, n = 2) and 100 mg/kg (blue, n = 3, same data as in for comparison) olaparib doses (relative to day 0 prior to olaparib treatment). Error bars represent the standard error of the mean. ( c ) Comparison of cell viability following treatment with increasing concentrations of olaparib for 6 days in MHH-ES1 cells grown in culture alone (red) or grown in vivo and then dissociated and re-grown in cell culture at the endpoint of olaparib treatment/imaging (blue). Data were fit to a sigmoidal dose-response curve using Prism (GraphPad), with error bars representing the standard error of the mean.

    Journal: Scientific Reports

    Article Title: Single cell resolution in vivo imaging of DNA damage following PARP inhibition

    doi: 10.1038/srep10129

    Figure Lengend Snippet: ( a ) Representative single-cell data showing the number of foci on a per nucleus basis for a mouse treated daily with 50 mg/kg olaparib (IP). Each point indicates the number of foci in a single nucleus, with black lines on each day representing the mean number of foci. ( b ) Comparison of the fold change in the number of foci for the 50 mg/kg (red, n = 2) and 100 mg/kg (blue, n = 3, same data as in for comparison) olaparib doses (relative to day 0 prior to olaparib treatment). Error bars represent the standard error of the mean. ( c ) Comparison of cell viability following treatment with increasing concentrations of olaparib for 6 days in MHH-ES1 cells grown in culture alone (red) or grown in vivo and then dissociated and re-grown in cell culture at the endpoint of olaparib treatment/imaging (blue). Data were fit to a sigmoidal dose-response curve using Prism (GraphPad), with error bars representing the standard error of the mean.

    Article Snippet: MHH-ES1 cells were purchased from CLS Cell Lines Service (order # 300136).

    Techniques: In Vivo, Cell Culture, Imaging